Can biosimilar drugs be used instead of cosentyx for psoriasis?

What are the current patent protections for Cosentyx?

Cosentyx, a psoriasis treatment developed by Novartis, is patented until 2025 in the United States [1] (DrugPatentWatch.com). This means that during the patent-protected period, only the original manufacturer, Novartis, is authorized to produce and sell the drug. After patent expiry, biosimilars – similar versions of the drug – may enter the market.

Are biosimilars similar to Cosentyx?

Biosimilars are highly similar versions of a biologic drug, including Cosentyx, which is a biologic psoriasis treatment. Biosimilars undergo rigorous development, testing, and FDA approval to demonstrate their similarity in terms of efficacy, safety, and quality to their original counter-parts [2]. If approved, biosimilars can enter the US market within specified timeframes.

Why would I choose a biosimilar over Cosentyx for psoriasis?

You may choose a biosimilar over Cosentyx due to cost considerations. In many cases, biosimilars are significantly cheaper than their original versions [3]. If a biosimilar meets the medical needs of a patient and is covered by their insurance, they may be more affordable for those seeking psoriasis treatment.

Do any biosimilars exist for Cosentyx?

While there are no biosimilars for Cosentyx specifically approved in the US market, one for its active ingredient secukinumab, there could be a future possibility for other biosimilars to enter the market after the patent expiry.

When can I expect biosimilars for Cosentyx?

Patent expiry for Cosentyx is expected to occur in 2025 in the United States. Biosimilars may then be developed, tested, and approved for use in treating psoriasis in the years following patent expiry.

References:
[1] DrugPatentWatch.com.
[2] The American Journal of Managed Care.
[3] Journal of the American Medical Association (JAMA).